Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05075564 · ClinicalTrials.gov registry record · Phase 1

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Elpiscience Biopharma.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
7
Study locations

NCT05075564: Completed Phase 1 study of Advanced Solid Tumor, sponsored by Elpiscience Biopharma.

NCT05075564 is a Phase 1 study of Advanced Solid Tumor that has completed, run by Elpiscience Biopharma. The registered enrollment target is 8 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05075564, a Phase 1 study of Advanced Solid Tumor, has completed, sponsored by Elpiscience Biopharma.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with advanced solid tumors that are relapsed or refractory to standard therapies.

Primary Outcome

Adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Part 1 ES002023
  • DRUG Part 2 ES002023

Study Locations (7)

Arizona

  • HonorHealth - Scottsdale

Arkansas

  • Fayetteville Oncology - Fayetteville

California

  • UCLA - Los Angeles

Florida

  • Sarah Cannon Research Institute - Orlando

New Jersey

  • Cancer Institute of New Jersey - New Brunswick

Texas

  • NEXT Austin - Austin

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-12-23
Est. Completion 2022-10-13
Phase Phase 1
Elpiscience Biopharma

1 total trials

What the finished NCT05075564 record still lists

NCT05075564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Part 1 ES002023 is the first listed.

NCT05075564 lists 7 locations in 7 states (Arizona, Arkansas, California).

Frequently Asked Questions

What is clinical trial NCT05075564 about?

NCT05075564 is a clinical study titled "A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors". The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with advanced solid tumors that are relapsed or refractory to standard ther...

What is the current status of trial NCT05075564?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-12-23. Estimated completion is 2022-10-13.

What conditions does trial NCT05075564 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05075564?

The interventions under investigation include: Part 1 ES002023 (DRUG), Part 2 ES002023 (DRUG).

Who is sponsoring clinical trial NCT05075564?

This trial is sponsored by Elpiscience Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05075564 being conducted?

This trial has 7 study locations across Arizona, Arkansas, California, Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05075564's enrollment target sits among peer trials

8 189th of 189 the lowest of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05075564, the US trial registry maintained by the National Library of Medicine. NCT05075564 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.